About: Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease
Creator	Li, Qinfan Xiaohua, • Lin, • Chen, Tanzhou Dong, Xiuli Huang, Zhiming Xie, Saili Xiangrong, Ye
source	Medline; PMC
abstract	BACKGROUND: Fibrinogen-like protein 2 (FGL2), a new member of the fibrinogen-like family, has recently been identified as a novel immunosuppressive molecule. AIM: The purpose of this work was to investigate intestinal and peripheral expression of FGL2 in patients with inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) and Crohn’s disease (CD). METHODS: FGL2 expression in mucosal biopsies from three groups (UC group (n = 61), CD group (n = 54), and controls group (n = 35)) was detected by immunohistochemistry. Concentrations of FGL2 in plasma from 50 UC patients, 45 CD patients, and 30 controls were analyzed by enzyme-linked immunosorbent assay. Western blot of FGL2 protein and real-time fluorescent quantitative PCR of FGL2 mRNA expression by peripheral mononuclear cells was performed. Correlations of FGL2 expression with disease type, activity, and location, and with measured laboratory data, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), were examined. RESULTS: Intestinal and peripheral FGL2 protein data showed that FGL2 expression was significantly up-regulated in both UC and CD patients compared with controls (P < 0.001). Expression of FGL2 was higher in UC and CD patients with active disease than in those with inactive disease (P < 0.001). Moreover, FGL2 mRNA expression was significantly higher in patients with active disease than in those with inactive disease (P < 0.050). Expression of FGL2 protein was correlated with disease activity indices, CRP levels, and ESR levels. CONCLUSION: Expression of FGL2 was up-regulated in IBD patients with active disease. Measurement of FGL2 may be used as a helpful biomarker for understanding immunopathogenesis and for assessment of IBD.
has issue date	2013-11-28(xsd:dateTime)
bibo:doi	10.1007/s10620-013-2962-9
bibo:pmid	24287641
has license	no-cc
sha1sum (hex)	6d3fec32bbc22df9abff1149c1c43e17f71095cd
schema:url	https://doi.org/10.1007/s10620-013-2962-9
resource representing a document's title	Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease
has PubMed Central identifier	PMC7087870
has PubMed identifier	24287641
schema:publication	Dig Dis Sci
resource representing a document's body	covid:6d3fec32bbc22df9abff1149c1c43e17f71095cd#body_text
is schema:about of	named entity 'molecule' named entity 'Expression' named entity 'disease' named entity 'expression' named entity 'peripheral' named entity 'expression' named entity 'correlated' named entity 'helpful' named entity 'patients' named entity 'expression' named entity 'Inflammatory Bowel Disease' named entity 'EXPRESSION' named entity 'ERYTHROCYTE SEDIMENTATION RATE' named entity 'FLUORESCENT' named entity 'QUANTITATIVE PCR' named entity 'C-REACTIVE PROTEIN' named entity 'BIOMARKER' named entity 'FIBRINOGEN-LIKE PROTEIN 2' named entity 'PERIPHERAL' named entity 'INACTIVE DISEASE' named entity 'INFLAMMATORY BOWEL DISEASE' named entity 'TO INVESTIGATE' named entity 'USED' named entity 'LABORATORY DATA' named entity 'UNDERSTANDING' named entity 'ACTIVE' named entity 'EXAMINED' named entity 'DISEASE ACTIVITY' named entity 'INCLUDING' named entity 'EXPRESSION' named entity 'WORK' named entity 'ESR' named entity 'IBD' named entity 'CONCLUSION' named entity 'IDENTIFIED' named entity 'BACKGROUND' named entity 'FIBRINOGEN' named entity 'FGL2' named entity 'LIKE' named entity 'GROUPS' named entity 'MEASURED' named entity 'INTESTINAL' named entity 'INFLAMMATORY BOWEL DISEASE' named entity 'PROTEIN DATA' named entity '050' named entity 'COMPARED' named entity 'PERIPHERAL' named entity 'FIBRINOGEN-LIKE PROTEIN 2' named entity 'WESTERN BLOT' named entity 'DISEASE' named entity 'INTESTINAL' named entity 'GROUP' named entity 'ENZYME-LINKED IMMUNOSORBENT ASSAY' named entity 'PATIENTS' named entity 'LOCATION' named entity 'LEVELS' named entity 'ACTIVITY' named entity 'MEASUREMENT' named entity 'ASSESSMENT' named entity '0.001' named entity 'RECENTLY' named entity '27S' named entity 'MOLECULE' named entity 'MAY BE' named entity 'CONCENTRATIONS' named entity 'CRP' named entity 'ULCERATIVE COLITIS' named entity 'PURPOSE' named entity 'FAMILY' named entity 'NEW' named entity 'ANALYZED' named entity 'UP-REGULATED' named entity 'IMMUNOHISTOCHEMISTRY' named entity 'MUCOSAL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software